今年2月28日是第19个国际罕见病日，旨在提升社会对各类罕见疾病的关注与认知。 重症肌无力是一种慢性自身免疫性疾病，主要分为眼肌型和全身型。2018年，全身型重症肌无力被纳入 国家第一批罕见病目录。该病病程长、易复发，严重影响患者的日常生活和工作，急性加重时亦可危及 生命。 面对这一疾病，吉林大学白求恩第一医院神经内科主任医师邓晖强调，规范治疗是基础。急性期症状缓 解后，患者应坚持足疗程的巩固治疗，降低复发风险；对于非急性期患者，应力求尽早实现双达标—— 既要控制好症状，又要最大限度减少药物副作用，从而更快、更好地回归正常生活。 "治疗不仅要追求'双达标'，更要尽早实现'双达标'，这样患者才能更快地回归高质量的生活。"邓晖 说。 临床上，有些患者在急性发作住院、症状好转出院后，感觉身体恢复了，便自行停药。 现实中，一部分处于非急性期的患者，长期依赖胆碱酶抑制剂、糖皮质激素或免疫抑制剂等传统药物， 虽然控制住了部分症状，但仍面临疗效不够理想、副作用影响生活等问题。 "这其实很危险。"邓晖指出，急性发作后出院的一年内，仍是复发高危期。表面上症状缓解了，但免疫 紊乱尚未完全恢复，身体对感染的抵抗力仍比较弱。一次普通 ...

Core Insights - Myasthenia gravis is characterized by muscle fatigue and weakness due to the immune system attacking acetylcholine receptors, leading to signal transmission issues between nerves and muscles [3][5] - The disease has distinct symptoms, including "morning light, evening heavy" patterns and fluctuating symptoms, with eye-related issues often being the first sign [3][4] - Diagnosis is crucial due to similarities with other conditions, utilizing methods like blood antibody tests and CT scans [7] Summary by Sections Disease Overview - Myasthenia gravis is an autoimmune disease where the immune system produces antibodies that attack acetylcholine receptors, impairing muscle signal transmission [3] - Symptoms include muscle weakness, particularly in the eyes, throat, and limbs, which worsen with activity and improve with rest [4] Demographics and Risk Factors - The disease can occur at any age, with peaks in young women (20s-30s) and older men (50s-60s), and a rising trend in patients over 50 [5] - Potential triggers include thymus abnormalities, genetic predisposition, infections, and certain medications [5][6] Diagnosis and Treatment - Accurate diagnosis is essential due to symptom overlap with other neurological conditions, employing tests like the edrophonium test and antibody detection [7] - Treatment focuses on symptom management and quality of life, with options including symptomatic treatment, immunotherapy, and thymectomy [7] Patient Management and Lifestyle - Patients are advised to engage in gentle aerobic exercises, maintain a balanced diet, and adhere to medication regimens to manage symptoms effectively [8] - Regular follow-ups are critical for monitoring treatment efficacy and preventing disease recurrence [8]

Core Insights - The article discusses the complex medical case of a 56-year-old woman suffering from multiple health issues, including myasthenia gravis and complications from a colon perforation, which required advanced surgical intervention [1][3][4]. Group 1: Patient Condition and Initial Treatment - The patient, suffering from myasthenia gravis, experienced a spontaneous colon perforation leading to severe infections and complications post-surgery, including colostomy-related issues [1][3]. - Initial treatment involved abdominal washing, partial resection of the sigmoid colon, and colostomy, but resulted in further complications such as colonic fistula and severe infections [3][4]. Group 2: Surgical Intervention - The surgical team at Southeast University Affiliated Zhongda Hospital, led by Dr. Tao Qingsong, performed a complex laparoscopic surgery to address the colonic fistula and restore normal bowel function [4]. - The surgery included left hemicolectomy, adhesiolysis, colostomy reversal, and abdominal wall reconstruction, with minimal blood loss of only 100 milliliters [4]. Group 3: Post-Surgery Recovery - Post-operative care involved close monitoring in the intensive care unit, followed by a tailored rehabilitation plan to ensure recovery of bowel function and overall health [4]. - The patient showed significant improvement, was able to mobilize shortly after surgery, and did not experience any complications such as recurrent infections [4]. Group 4: Medical Insights and Recommendations - Experts highlighted that infections are a significant factor in the deterioration of myasthenia gravis, often leading to respiratory failure and swallowing difficulties [5]. - Recommendations for myasthenia gravis patients include strict hygiene practices and immediate medical attention for any signs of infection or worsening symptoms [5].

Group 1: ALS (Amyotrophic Lateral Sclerosis) - ALS is a neurodegenerative disease with an increasing incidence rate in China, currently at 1.62 per 100,000 people, with nearly 24,000 new cases annually [2][3] - The average diagnosis time for ALS is between 10 months to 1 year, and the typical survival time after diagnosis is 3 to 5 years [2][3] - There are over 10 ALS treatment drugs in clinical trials, with some targeting specific genetic mutations like SOD1 [1][3] Group 2: Myasthenia Gravis (MG) - MG is an autoimmune disease with a prevalence of approximately 6.8 per million people in China, primarily affecting young women [5][6] - Recent advancements have led to the approval of targeted therapies for MG, with eight innovative biological drugs available, two of which are included in the medical insurance directory [6][7] - The quality of life for MG patients has improved significantly, with reduced medical burdens reported in recent studies [6][7] Group 3: Spinal Muscular Atrophy (SMA) - SMA is a highly fatal and disabling genetic disorder, with an incidence rate of about 1 in 10,000 newborns, and a carrier rate of approximately 2% in the general population [10][11] - The disease is categorized into four types based on age of onset and maximum motor function achieved, with Type I being the most severe [11] - Genetic screening is recommended for high-risk individuals to prevent the birth of affected children, although there is currently no mandatory screening for all pregnant women in China [12][13] Group 4: Rare Disease Landscape - Approximately 40% of the rare diseases listed are neurological disorders, which are the most numerous and complex among rare diseases [13] - There is a growing recognition of the potential for treatment and clinical cures for these neurological conditions, emphasizing the importance of awareness and understanding [13]

Core Viewpoint - The article highlights the challenges faced by myasthenia gravis patients in China, emphasizing the need for improved diagnosis, treatment accessibility, and social support systems for this rare disease [1][2][10]. Group 1: Disease Overview - Myasthenia gravis is an autoimmune neuromuscular disorder that affects nerve-muscle transmission, with approximately 650,000 patients in China [1][5]. - The annual incidence rate of myasthenia gravis in China is about 0.68 per 100,000, meaning one person is diagnosed every 14.7 years among 100,000 people [5]. - Misdiagnosis is a significant issue, with a reported misdiagnosis rate of 58.3% among surveyed patients [3][5]. Group 2: Patient Challenges - Patients face numerous challenges, including high treatment costs, lack of insurance coverage for essential medications, and social discrimination [10][11]. - Approximately 40.9% of surveyed patients reported having no income, and 46.3% earn less than 5,000 yuan per month, making it difficult to afford long-term treatment [10]. - 70% of patients are unable to work full-time due to their condition, and 29.8% experienced a relapse in the past six months [6][10]. Group 3: Treatment and Management - Advances in treatment have led to a shift from immunosuppressive therapies to "immune resetting," with potential for clinical remission [7]. - New drug developments, such as CAR-T cell therapy, show promise in improving treatment outcomes [7]. - The article emphasizes the importance of timely and appropriate treatment to achieve clinical improvement [7]. Group 4: Social Support and Advocacy - The establishment of patient organizations, such as the Beijing Aili Myasthenia Gravis Rare Disease Care Center, plays a crucial role in providing support and advocacy for patients [15]. - The article calls for a redefinition of myasthenia gravis to enhance public understanding and reduce stigma [15]. - Continued efforts are needed to improve social support systems and reduce the economic burden on patients and their families [14].

Core Viewpoint - The article highlights the challenges faced by patients with myasthenia gravis, a rare autoimmune disease, including misdiagnosis, treatment difficulties, and the need for better healthcare support and awareness [1][4][11]. Group 1: Patient Challenges - Patients with myasthenia gravis often experience symptoms such as sudden weakness, drooping eyelids, and difficulty swallowing, leading to misdiagnosis as psychological issues or other conditions [3][4]. - The prevalence of myasthenia gravis is approximately 7.4 per million people, translating to around 650,000 patients in China due to the large population [4][7]. - Many patients report being misdiagnosed for years, which delays appropriate treatment and exacerbates their condition [3][4]. Group 2: Treatment and Healthcare Support - Current treatments for myasthenia gravis include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but many essential medications are not covered by insurance, leading to high out-of-pocket costs [7][8]. - The new national medical insurance drug list, effective January 1, 2024, includes two medications for myasthenia gravis, but patients still face significant financial burdens for ongoing and crisis treatments [7][8]. - Experts suggest that myasthenia gravis should be included in outpatient chronic disease categories to improve reimbursement rates and access to necessary medications [8][9]. Group 3: Psychological and Social Aspects - The psychological impact of myasthenia gravis is significant, with many patients facing discrimination and social stigma due to visible symptoms like drooping eyelids [11]. - A study indicated that 17.1% of surveyed patients experienced discrimination affecting their work and study opportunities, highlighting the need for greater societal awareness and support [11]. - Mental health support is emphasized as a crucial component of treatment, alongside physical health interventions [11].

新京报讯3月31日，国家药监局网站显示，罗泽利昔珠单抗注射液(商品名为优迪革)获得批准，与常规 治疗药物联合用于治疗乙酰胆碱受体(AChR)或肌肉特异性受体酪氨酸激酶(MuSK)抗体阳性的成人全身 型重症肌无力(gMG)患者。该药也是全球首个且唯一同时覆盖AChR阳性和MuSK阳性gMG的新生儿Fc 受体(FcRn)拮抗剂，此次获批填补了国内MuSK阳性患者靶向治疗的空白。 复旦大学附属华山医院神经内科主任医师、中国重症肌无力协作组组长赵重波教授指出，相较于其他罕 见病，重症肌无力的诊断相对明确，通过积极且规范的治疗，大多数患者的病情能够得到有效控制，但 病情控制住并不等同于生活质量的全面恢复。罗泽利昔珠单抗注射液获批上市，不仅填补了MuSK抗体 阳性患者靶向治疗的空白，也为重症肌无力患者提供了更具针对性的治疗选择，这对改善患者生活质量 及促进其回归正常生活具有重要意义。 重症肌无力是一种自身免疫性神经肌肉传递障碍罕见疾病，可引起明显的肌无力、疲劳等症状，导致言 语、行动、呼吸等身体功能受限，或合并胸腺瘤，疾病加重至肌无力危象(累及呼吸肌导致呼吸衰竭)可 危及生命。数据显示，我国重症肌无力年发病率为0.68/ ...